Medical/Pharmaceuticals
Concord Medical Files 2021 Annual Report on Form 20-F
BEIJING, April 29, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers, premium cancer hospitals, and specialty can...
2022-04-30 07:15
3757
Global Cord Blood Corporation Announces Entry into Cell Therapy Market by Acquiring Cellenkos and Its Products Rights
HONG KONG, April 30, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, announced today that the Company will acquire 100% ...
2022-04-30 04:16
9181
Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals
LONDON, April 30, 2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation an...
2022-04-30 02:08
2614
Antengene Announces Latest Clinical Trial Data of ATG-008 (onatasertib) to be presented in the upcoming 2022 American Society of Clinical Oncology Annual Meeting
SHANGHAI and HONG KONG, April 29, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and onc...
2022-04-29 22:30
2766
IONOVA Announces Clinical Trial Collaboration with MSD to Evaluate INV-1120 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
SHENZHEN, China, April 29, 2022 /PRNewswire/ -- Shenzhen IONOVA Life Science Co., Ltd. announces today it has entered into a clinical trial collaboration agreement with MSD (Merck & Co., Inc., Kenilworth, NJ., USA) to evaluate clinical benefits of INV-1120, IONOVA's EP4 antagonist, in combination...
2022-04-29 20:00
1045
Biocytogen Enters into Antibody Agreement with Merck
BEIJING, April 29, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) announced that it has entered into an evaluation and option agreement with Merck to grant them a sole license to evaluate Biocytogen's proprietary antibodies against at least three distinct targets...
2022-04-29 20:00
2516
New IFPA report reveals link between psoriatic disease and mental health
STOCKHOLM, April 29, 2022 /PRNewswire/ -- Psoriatic disease is an inflammatory illness that affects the skin and joints. Itchy, flaky patches of skin are perhaps the most common symptom. But psoriatic disease goes far deeper. For many, one of the most difficult challenges in living with psoriatic...
2022-04-29 14:00
2273
Asia Pacific Initiative on Reproduction (ASPIRE) 2022 Congress: Greater sense of patient empowerment with telemedicine trends in IVF services
SINGAPORE, April 29, 2022 /PRNewswire/ -- Telemedicine that became a vital engagement tool between health professionals and patients during the COVID-19 pandemic is emerging as a welcome new treatment of choice among fertility clinics and couples striving for parenthood. Patients seeking assiste...
2022-04-29 10:50
4181
Transcenta to Present Clinical Trial Data of TST001 and MSB0254 at 2022 ASCO Annual Meeting
SUZHOU, China, April 29, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the abstracts o...
2022-04-29 10:33
2657
I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer
- Biotech and Wall Street veteran Mr. Richard Yeh to focus on strategic investor interactions, global alliance management and facilities as COO - Renowned oncology expert Dr. John Hayslip to further accelerate global clinical development of I-Mab's innovative pipeline as CMO SHANGHAI and GAITHE...
2022-04-29 04:01
1503
Promising COVID oral antiviral being co-researched by Healion Bio and FUJIFILM Toyama
FREDERICK, Md., April 29, 2022 /PRNewswire/ -- Healion Bio, a closely held biotechnology company, today announced a collaborative agreement to research a combination antiviral against SARS-CoV-2 and other deadly pathogens. The combination will include one of Healion Bio's protease inhibitors and ...
2022-04-29 01:00
2120
Varian partners with Icon Group to advance patient-centric solutions
Bringing clinical insights into early product development PALO ALTO, Calif. and SYDNEY, April 28, 2022 /PRNewswire/ -- Varian, a Siemens Healthineers company (Varian), today announced a five-year research and professional services agreement with Icon Group (Icon). Through this agreement, Icon wi...
2022-04-28 23:00
1999
Gracell Biotechnologies Announces Details of Oral Abstract Presentation at 2022 ASCO Annual Meeting
Gracell to present longer-term follow-up clinical data evaluating GC012F, an autologous CAR-T therapeutic candidate dual-targeting BCMA and CD19, for the treatment of relapsed/refractory multiple myeloma SAN DIEGO, Calif. and SUZHOU, China, April 28, 2022 /PRNewswire/ -- Gracell Biotechnologies ...
2022-04-28 22:30
1832
Lunit to Present 11 Abstracts at the 2022 ASCO Annual Meeting
* 7 poster presentations and 4 online publications, including research on AI biomarkers, have been accepted by ASCO * Findings demonstrate the practical effectiveness of Lunit's AI solution in the pathological assessment of cancer SEOUL, South Korea, April 28, 2022 /PRNewswire/ -- Lunit today...
2022-04-28 21:33
1445
Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment after Cataract Surgery at ARVO 2022 Annual Meeting
TAIPEI, April 28, 2022 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWO.6838
2022-04-28 20:00
1211
HanAll Biopharma Reports First Quarter 2022 Results and Provides Business Update
* HanAll will expand R&D investments to advance its late-stage pipeline assets SEOUL, South Korea, April 28, 2022 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), a global biopharma company committed to deliver innovative and impactful therapeutics to address severe unmet medical needs, tod...
2022-04-28 19:00
1405
United Imaging Healthcare bags Healthcare Asia Medtech Award
SHANGHAI, April 28, 2022 /PRNewswire/ -- United Imaging Healthcare was recognised with the Imaging Product Innovation of the Year Award at the Healthcare Asia Medtech Awards with its three groundbreaking products: the Total-body PET/CT uEXPLORER, the 3.0T uMR Omega, and uRT-linac 506c. United Im...
2022-04-28 18:28
2931
Transcenta Announces First Patient Dosed in China Study of Anti-sclerostin Monoclonal Antibody TST002 for the Treatment of Osteoporosis
SUZHOU, China, April 28, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the successful dosin...
2022-04-28 17:06
1869
The Danish National Genome Center Partners with Lifebit to Deliver Nationwide Personalised Medicine
The Danish National Genome Center has awarded Lifebit a four-year contract to implement Lifebit's Federated Trusted Research Environment software, Lifebit CloudOS, withinDenmark's national supercomputing center. LONDON, April 28, 2022 /PRNewswire/ -- Lifebit, whose leading technology enable...
2022-04-28 14:00
2346
WuXi Biologics' 2021 ESG Report Reveals Company's Strong Commitment to Overall Sustainability
- WuXi Biologics has aligned its ESG strategy with the United Nations Sustainable Development Goals (SDGs), as well as with its stakeholders' interests in sustainable business performance. - One example of WuXi Biologics' contribution to society is its rapid, robust pandemic response -- enab...
2022-04-28 08:30
1589
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 273 media titles]
2024-04-24 17:09
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
6229
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
2024-04-22 16:00
4457
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
2024-04-22 06:00
4051
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
2024-04-24 17:09
2944
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
2024-04-23 15:43
2892